Morgan Stanley
GRCL

Morgan Stanley’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Morgan Stanley’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-78,119
Closed -$784K – 8063
2023
Q4 		$784K Sell
78,119
-20,529
-21% -$93.2K ﹤0.01% 5071
2023
Q3 		$284K Buy
98,648
+74,275
+305% +$272K ﹤0.01% 5427
2023
Q2 		$92.9K Sell
24,373
-471
-2% -$1.32K ﹤0.01% 5989
2023
Q1 		$46.2K Buy
24,844
+2,549
+11% +$5.33K ﹤0.01% 6319
2022
Q4 		$51.3K Sell
22,295
-196,813
-90% -$603K ﹤0.01% 6281
2022
Q3 		$705K Sell
219,108
-329,927
-60% -$1.07M ﹤0.01% 5089
2022
Q2 		$3.02M Sell
549,035
-78,758
-13% -$245K ﹤0.01% 4204
2022
Q1 		$1.46M Buy
627,793
+21,662
+4% +$73.8K ﹤0.01% 4737
2021
Q4 		$3.66M Sell
606,131
-357,204
-37% -$3.43M ﹤0.01% 4051
2021
Q3 		$13.4M Sell
963,335
-68,420
-7% -$808K ﹤0.01% 2563
2021
Q2 		$13.4M Buy
1,031,755
+110,725
+12% +$1.48M ﹤0.01% 2627
2021
Q1 		$14.2M Buy
+921,030
New +$21.7M ﹤0.01% 2283

Morgan Stanley's GRCL Position: Q1 2024 in Review

Morgan Stanley sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 78,119 shares — an estimated $784K sold.

Morgan Stanley first reported a position in GRCL in Q1 2021 and held it in 12 quarters. The position peaked at $14.2M in Q1 2021. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

  • Morgan Stanley reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Morgan Stanley sold 78,119 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $784K.
  • Morgan Stanley first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2021 and held it in 12 quarters.
  • Morgan Stanley's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $14.2M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Morgan Stanley's 13F filing for Q1 2024, filed 15 May 2024.